{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003111","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.311564+00:00","generated_at":"2026-06-15T11:06:56.775254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Psychemedics Q1 revenue down 10% to $5.9M, net loss of $384K; declares $0.07 dividend","bullets":["Net loss of $384K ($0.07 diluted loss) vs net income of $39K ($0.01 diluted) in Q1 2022.","Revenue fell 10% to $5.9M from $6.5M, driven by labor shortage and inflationary pressures.","Gross margin held flat at 38% due to cost reductions implemented in Q4 2022.","Cash balance $4.4M, equipment financing $0.5M; dividend of $0.07/share payable June 8 to record May 25.","Oil & Gas, Railroad, School segments performed solidly; fentanyl and benzodiazepine add-on test sales grew."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003111","json":"https://secwatch.observer/filing/0001171843-23-003111.json","markdown":"https://secwatch.observer/filing/0001171843-23-003111.md","text":"https://secwatch.observer/filing/0001171843-23-003111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184323003111/0001171843-23-003111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184323003111/f8k_050923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:06:56.775254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bd61bda085f476f3604768b0368cd60af93afed","claim":"PSYCHEMEDICS CORP reported the first quarter ended March 31, 2023 results: revenue $5.9 million, net income $(384,000), EPS $(0.07) per diluted share.","evidence_excerpt":"The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184323003111/0001171843-23-003111-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$5.9 million"},{"label":"Net income","value":"$(384,000)"},{"label":"EPS","value":"$(0.07) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}